During the past decade, University of Chicago; Neurology conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Chicago; Neurology" #1 sponsor was "Genentech, Inc." with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "AB Science" with 1 trials sponsored, "Columbia University" with 1 trials sponsored and "University of Chicago" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Chicago; Neurology" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "Michael J. Fox Foundation for Parkinson's Research" with 1 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "University of Chicago; Neurology" are "Amyotrophic Lateral Sclerosis" (2 trials), "Alzheimer Disease" (1 trials), "Lou Gehrig's Disease" (1 trials), "Multiple Sclerosis, Relapsing" (1 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "University of Chicago; Neurology" in a lesser frequency.

Most popular intervention types in "University of Chicago; Neurology" are "Drug" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Ocrelizumab" (2 trials), "Avonex" (1 trials), "Deep Brain Stimulation (DBS) Off (Sham)" (1 trials) and "Deep Brain Stimulation (DBS) at 130 Hz" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Chicago; Neurology" are 7 trials for "All" genders.

Currently, there are NaN active trials in "University of Chicago; Neurology". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of Chicago; Neurology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Chicago; Neurology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".